The case for therapeutic proteostasis modulators

Bibliography

• Seifert U, Bialy LP, Ebstein F, Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010;142:613-24
   PubMed Web of Science ®Google Scholar
• Zoeger A, Blau M, Egerer K, Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin Chem 2006;52:2079-86
   PubMed Web of Science ®Google Scholar
• Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res 2005;569:29-63
   PubMed Web of Science ®Google Scholar
• Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. Physiol Rev 2006;86:1133-49
   PubMed Web of Science ®Google Scholar
• Zhang K, Wong HN, Song B, The unfolded protein response sensor IRE1alpha is required at 2 distinct steps in B cell lymphopoiesis. J Clin Invest 2005;115:268-81
   PubMed Web of Science ®Google Scholar
• Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005;74:739-89
   PubMed Web of Science ®Google Scholar
• Dahlmann B. Role of proteasomes in disease. BMC Biochem 2007;8(Suppl 1):S3
   PubMedGoogle Scholar
• Ferrer I, Martin B, Castano JG, Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004;63:484-98
   PubMedGoogle Scholar
• Diaz-Hernandez M, Martin-Aparicio E, Avila J, Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. Neurotox Res 2004;6:463-8
   PubMed Web of Science ®Google Scholar
• Kotamraju S, Matalon S, Matsunaga T, Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Radic Biol Med 2006;40:1034-44
   PubMed Web of Science ®Google Scholar
• Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant 2001;16(Suppl 1):60-2
   PubMedGoogle Scholar
• Moreno-Lopez B, Gonzalez-Forero D. Nitric oxide and synaptic dynamics in the adult brain: physiopathological aspects. Rev Neurosci 2006;17:309-57
   PubMed Web of Science ®Google Scholar
• Niedbala W, Cai B, Liew FY. Role of nitric oxide in the regulation of T cell functions. Ann Rheum Dis 2006;65(Suppl 3):iii37-40
   PubMedGoogle Scholar
• Thomas DD, Espey MG, Ridnour LA, Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 2004;101:8894-9
   PubMed Web of Science ®Google Scholar
• Stratford FL, Chondrogianni N, Trougakos IP, Proteasome response to interferon-gamma is altered in senescent human fibroblasts. FEBS Lett 2006;580:3989-94
   PubMed Web of Science ®Google Scholar
• Meiners S, Heyken D, Weller A, Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes. J Biol Chem 2003;278:21517-25
   PubMed Web of Science ®Google Scholar
• Stangl V, Lorenz M, Meiners S, Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J 2004;18:272-9
   PubMedGoogle Scholar
• Meiners S, Ludwig A, Lorenz M, Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med 2006;40:2232-41
   PubMedGoogle Scholar
• Qian SB, Zhang X, Sun J, mTORC1 links protein quality and quantity control by sensing chaperone availability. J Biol Chem 2010;285:27385-95
   PubMed Web of Science ®Google Scholar
• Henninger N, Sicard KM, Bouley J, The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia. Neurosci Lett 2006;398:300-5
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang ZG, Liu X, Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost 2006;95:166-73
   PubMed Web of Science ®Google Scholar
• Williamson MJ, Blank JL, Bruzzese FJ, Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther 2006;5:3052-61
   PubMed Web of Science ®Google Scholar
• Mitchell BS. The proteasome – an emerging therapeutic target in cancer. N Engl J Med 2003;348:2597-8
   PubMed Web of Science ®Google Scholar
• Bross PF, Kane R, Farrell AT, Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-64
   PubMed Web of Science ®Google Scholar
• Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13
   PubMed Web of Science ®Google Scholar
• Shah IM, Lees KR, Pien CP, Elliott PJ. Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol 2002;54:269-76
   PubMed Web of Science ®Google Scholar
• Jakob C, Egerer K, Liebisch P, Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007;109:2100-5
   PubMed Web of Science ®Google Scholar